1. Home
  2. STTK vs TACO Comparison

STTK vs TACO Comparison

Compare STTK & TACO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.54

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Logo Berto Acquisition Corp. Ordinary Shares

TACO

Berto Acquisition Corp. Ordinary Shares

N/A

Current Price

$10.52

Market Cap

393.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
TACO
Founded
2016
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
393.2M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
STTK
TACO
Price
$4.54
$10.52
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $15.40
N/A
AVG Volume (30 Days)
★ 841.6K
214.6K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 53.02
N/A
EPS
N/A
★ 0.29
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$14.28
N/A
P/E Ratio
★ N/A
$36.29
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$10.11
52 Week High
$8.33
$10.59

Technical Indicators

Market Signals
Indicator
STTK
TACO
Relative Strength Index (RSI) 36.65 67.98
Support Level $4.38 $10.44
Resistance Level $7.66 $10.55
Average True Range (ATR) 0.39 0.01
MACD -0.02 0.00
Stochastic Oscillator 13.92 88.89

Price Performance

Historical Comparison
STTK
TACO

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TACO Berto Acquisition Corp. Ordinary Shares

Berto Acquisition Corp is a blank check company.

Share on Social Networks: